Abstract
Antibody light chains of the κ subgroup are the predominant light chain component in human immune responses and are used almost exclusively in the antibody repertoire of mice. Human κ light chains comprise four subgroups. To date, all crystallographic studies of human κ light chains were carried out on proteins of the κI subgroup. The light chain produced by multiple myeloma patient Len, was of the κIV subgroup, it differed by only one residue from the germ-line gene encoded protein. The variable domain fragment of the light chain was crystallized from ammonium sulfate in space group C222 1. The crystal structure was determined by molecular replacement and refined at 1.95 Å resolution to an R-factor of 0.15. Protein Len has six additional residues in its CDR1 segment compared to the κI proteins previously characterized. The κIV variable domain. Len, differs in only 23 of 113 residues from murine κ light chain McPC603. The RMS deviation upon superimposing their α-carbons was 0.69 Å. The CDR1 segment of the human and murine variable domains have the same length and conformation although their amino acid sequences differ in 5 out of 17 residues. Structural features were identified that could account for the significantly higher stability of the human κIV protein relative to its murine counterpart. This human κIV light chain structure is the closest human homolog to a murine light chain and can be expected to facilitate detailed structural comparisons necessary for effective humanization of murine antibodies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.